The GLP-1 drug semaglutide may slow biological ageing and prolong life, based on a fresh investigation involving mature, healthy mice that received funding from the National Institutes of Health (NIH). Scientists at the University of California, Berkeley discovered that a three-month course of the treatment enhanced cognitive and muscle performance in older female rodents while lowering multiple biological indicators tied to ageing, suggesting potential advantages that extend past conventional metabolic therapies.
UC Berkeley Study Findings on Semaglutide and Ageing
Researchers led by Dr Danica Chen, Professor of Metabolic Biology and Nutrition at UC Berkeley, administered semaglutide to 20-month-old female mice for three months. According to the study, treated mice performed better in measures of muscle and cognitive function compared to untreated animals. Gene expression analysis further indicated reductions in several hallmarks of natural ageing, including increased inflammation and diminished regenerative capacity. Among a separate cohort tracked until their death, the NIH-backed study revealed that subjects given semaglutide had a median lifespan that exceeded that of unmedicated controls by nearly 100 days.
Comparing Semaglutide to Calorie Restriction
To determine if these effects stemmed simply from reduced food intake, the UC Berkeley team placed a group of 20-month-old female mice on a 24 percent calorie-restricted diet designed to match the feeding pattern of the semaglutide-treated group over five months. While most physiological measurements remained stable across both groups, semaglutide-treated mice exceeded baseline levels in exploratory behaviour, spatial memory, and blood-sugar regulation. Furthermore, metabolic rate fell in the calorie-restricted mice but remained largely unchanged among those receiving semaglutide, according to the researchers.
Did you know? In the NIH-funded lifespan study, 39 mice received saline and 40 mice received semaglutide via daily subcutaneous injections administered with a 28-gauge needle, with operators systematically rotating injection sites to minimize local tissue irritation.
Biological Mechanisms Independent of Diet
The distinct metabolic differences between the two groups suggest semaglutide operates through biological pathways separate from simple calorie reduction. “These differences point to the possibility that GLP-1 drugs tap into a biological pathway independent of calorie restriction,” said Dr Danica Chen, noting that uncovering this route is a key direction for future research. Dr Rafael de Cabo, a senior investigator at the NIH’s National Institute on Aging (NIA) and author of a commentary on the study, also noted that because aging serves as the primary foundation for most chronic illnesses, slowing it down with GLP-1 receptor agonists is anticipated to unlock a broad spectrum of medical benefits.
FAQs on Semaglutide and Longevity Research
Does semaglutide extend lifespan in humans?
Researchers stress that findings in mice cannot yet be assumed to apply to people. Further clinical research is needed to establish whether GLP-1 drugs can extend or improve healthy lifespan in humans.
How was the mouse study conducted?
C57BL/6 female mice aged 20 months received daily subcutaneous injections of 10 nmol per kg of semaglutide or an equal volume of saline. Researchers evaluated body composition, open-field behavior, metabolism, and survival rates.
What did the calorie-restriction comparison reveal?
While calorie restriction lowered metabolic rates, semaglutide treatment left metabolic rates largely unchanged while improving spatial memory, exploratory behavior, and blood-sugar regulation beyond baseline levels.
Want to stay updated on the latest breakthroughs in longevity science and metabolic research? Subscribe to our newsletter or share your thoughts in the comments below.
Related reading